Researchers working as part of the VIVALDI study have shed further light on the pattern of protection given to residents of long-term care facilities by COVID-19 booster doses.
A new version of the Moderna ‘bivalent' COVID-19 vaccine that targets both the original strain of SARS-CoV-2 and the Omicron BA.4 and BA.5 sub-variants has today been authorised for use in the UK by the Medicines and Healthcare products Regulatory Agency.
The team behind the MELODY study has shown that 23% of people with solid organ transplants, 21% of those with lymphoid malignancies and 14% of those with rare autoimmune rheumatic diseases have no detectable antibodies against COVID-19 despite three or more vaccine doses.
A team of researchers from the universities of Bristol, Leicester, Glasgow, UCL and King’s College London, have confirmed that the COVID-19 booster programme resulted in a substantial uplift in the UK population’s immunity.
A team led by researchers at Imperial College London have demonstrated a link between the microbes present in the gut and the strength of antibody response to the COVID-19 vaccines in people on certain treatments for inflammatory bowel disease.